Endocrinol Metab.  2013 Mar;28(1):55-60. 10.3803/EnM.2013.28.1.55.

Two Cases of Methimazole-Induced Insulin Autoimmune Syndrome in Graves' Disease

• Roh E
• Kim YA
• Ku EJ
• Bae JH
• Kim HM
• Cho YM
• Park YJ
• Park KS
• Kim SY
• Kwak SH

• KMID: 1805947
• DOI: http://doi.org/10.3803/EnM.2013.28.1.55

Abstract

We report here the cases of two females with Graves' disease who developed insulin autoimmune syndrome after treatment with methimazole. The patients exhibited a sudden altered mental state after treatment with methimazole for approximately 4 weeks. Patients had hypoglycemia with serum glucose below 70 mg/dL, and laboratory findings showed both high levels of serum insulin and high titers of insulin autoantibodies. The two women had never been exposed to insulin or oral antidiabetic agents, and there was no evidence of insulinoma in imaging studies. After glucose loading, serum glucose, and total insulin levels increased abnormally. One of the patient was found to have HLA-DRB1*0406, which is known to be strongly associated with methimazole-induced insulin autoimmune syndrome. After discontinuation of methimazole, hypoglycemic events disappeared within 1 month. Insulin autoantibody titer and insulin levels decreased within 5 months and there was no further development of hypoglycemic events. We present these cases with a review of the relevant literature.

Keyword

Graves disease; Insulin autoimmune syndrome; Methimazole

MeSH Terms

Autoantibodies
Female
Glucose
Graves Disease
HLA-DRB1 Chains
Humans
Hypoglycemia
Hypoglycemic Agents
Insulin
Insulinoma
Methimazole
Autoantibodies
Glucose
HLA-DRB1 Chains
Hypoglycemic Agents
Insulin
Methimazole

Reference

1. Hirata Y, Ishizu H, Ouchi N, Motomura S, Abe M, Hara Y, Wakasugi H, Takahashi I, Sakano H, Tanaka M. Insulin autoimmunity in a case with spontaneous hypoglycemia. J Jpn Diabetes Soc. 1970. 13:312–320.

2. Hirata Y, Tominaga M, Ito JI, Noguchi A. Spontaneous hypoglycemia with insulin autoimmunity in Graves' disease. Ann Intern Med. 1974. 81:214–218.

3. Ichihara K, Shima K, Saito Y, Nonaka K, Tarui S. Mechanism of hypoglycemia observed in a patient with insulin autoimmune syndrome. Diabetes. 1977. 26:500–506.

4. Hirata Y. Methimazole and insulin autoimmune syndrome with hypoglycemia. Lancet. 1983. 2:1037–1038.

5. Eisenbarth GS. Immunoendocrinology: scientific and clinical aspects. 2011. Totowa: Springer Science+Business Media;343–367. Chapter 21. Insulin autoimmune syndrome (Hirata disease).

6. Uchigata Y, Kuwata S, Tokunaga K, Eguchi Y, Takayama-Hasumi S, Miyamoto M, Omori Y, Juji T, Hirata Y. Strong association of insulin autoimmune syndrome with HLA-DR4. Lancet. 1992. 339:393–394.

7. Uchigata Y, Hirata Y, Omori Y, Iwamoto Y, Tokunaga K. Worldwide differences in the incidence of insulin autoimmune syndrome (Hirata disease) with respect to the evolution of HLA-DR4 alleles. Hum Immunol. 2000. 61:154–157.

8. Uchigata Y, Kuwata S, Tsushima T, Tokunaga K, Miyamoto M, Tsuchikawa K, Hirata Y, Juji T, Omori Y. Patients with Graves' disease who developed insulin autoimmune syndrome (Hirata disease) possess HLA-Bw62/Cw4/DR4 carrying DRB1*0406. J Clin Endocrinol Metab. 1993. 77:249–254.

9. Cho BY, Lee HK, Koh CS, Min HK. Spontaneous hypoglycemia and insulin autoantibodies in a patient with Graves' disease. Diabetes Res Clin Pract. 1987. 3:119–124.

10. Lee KS, Kim JH, Choi WH, Kim TW, Kim MH. A case report of insulin autoimmune syndrome in Graves' disease. J Korean Soc Endocrinol. 1993. 8:451–455.

11. Lim JK, Woo YA, Kang SJ, Yoo SS, Hong KY, Kim SH. Ensulin autoimmune syndrome in a patient with methimazole-treated Graves' disease: a case report. J Korean Soc Endocrinol. 1998. 13:612–616.

12. Takei M. Insulin autoantibodies produced by methimazole treatment in patients with Graves' disease. J Tokyo Women Med Coll. 1980. 50:54–68.

13. Uchigata Y, Eguchi Y, Takayama-Hasumi S, Omori Y. Insulin autoimmune syndrome (Hirata disease): clinical features and epidemiology in Japan. Diabetes Res Clin Pract. 1994. 22:89–94.

14. Takeuchi Y, Miyamoto T, Kakizawa T, Shigematsu S, Hashizume K. Insulin autoimmune syndrome possibly caused by alpha lipoic acid. Intern Med. 2007. 46:237–239.

15. Ito Y, Nieda M, Uchigata Y, Nishimura M, Tokunaga K, Kuwata S, Obata F, Tadokoro K, Hirata Y, Omori Y, et al. Recognition of human insulin in the context of HLA-DRB1* 0406 products by T cells of insulin autoimmune syndrome patients and healthy donors. J Immunol. 1993. 151:5770–5776.

16. Roh EY, Kim HS, Kim SM, Lim YM, Han BY, Park MH. HLA-A, -B, -DR allele frequencies and haplotypic associations in Koreans defined by generic-level DNA typing. Korean J Lab Med. 2003. 23:420–430.

17. Park MH, Park YJ, Song EY, Park H, Kim TY, Park DJ, Park KS, Cho BY. Association of HLA-DR and -DQ genes with Graves disease in Koreans. Hum Immunol. 2005. 66:741–747.

18. Eguchi Y, Uchigata Y, Yao K, Yokoyama H, Hirata Y, Omori Y. Longitudinal changes of serum insulin concentration and insulin antibody features in persistent insulin autoimmune syndrome (Hirata's disease). Autoimmunity. 1994. 19:279–284.

19. Yaturu S, DePrisco C, Lurie A. Severe autoimmune hypoglycemia with insulin antibodies necessitating plasmapheresis. Endocr Pract. 2004. 10:49–54.

20. Yu L, Herold K, Krause-Steinrauf H, McGee PL, Bundy B, Pugliese A, Krischer J, Eisenbarth GS. Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab selectively suppresses specific islet antibodies. Diabetes. 2011. 60:2560–2565.